Jones Angela R, Shusta Eric V
Department of Chemical and Biological Engineering, University of Wisconsin-Madison, 1415 Engineering Drive, Madison, Wisconsin 53706, USA.
Pharm Res. 2007 Sep;24(9):1759-71. doi: 10.1007/s11095-007-9379-0. Epub 2007 Jul 10.
Drug delivery to the brain is hindered by the presence of the blood-brain barrier (BBB). Although the BBB restricts the passage of many substances, it is actually selectively permeable to nutrients necessary for healthy brain function. To accomplish the task of nutrient transport, the brain endothelium is endowed with a diverse collection of molecular transport systems. One such class of transport system, known as a receptor-mediated transcytosis (RMT), employs the vesicular trafficking machinery of the endothelium to transport substrates between blood and brain. If appropriately targeted, RMT systems can also be used to shuttle a wide range of therapeutics into the brain in a noninvasive manner. Over the last decade, there have been significant developments in the arena of RMT-based brain drug transport, and this review will focus on those approaches that have been validated in an in vivo setting.
血脑屏障(BBB)的存在阻碍了药物向大脑的递送。尽管血脑屏障限制了许多物质的通过,但它实际上对健康大脑功能所需的营养物质具有选择性通透性。为了完成营养物质运输的任务,脑内皮细胞拥有多种分子运输系统。其中一类运输系统,称为受体介导的转胞吞作用(RMT),利用内皮细胞的囊泡运输机制在血液和大脑之间运输底物。如果靶向合适,RMT系统也可用于以非侵入性方式将多种治疗药物输送到大脑中。在过去十年中,基于RMT的脑药物运输领域取得了重大进展,本综述将重点关注那些在体内环境中得到验证的方法。